



Patent
45198.00037.CIP1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Erion et al.

Serial No.: 09/900,364

Filed: July 05, 2001

**For: A COMBINATION OF FBPA
INHIBITORS AND ANTIDIABETIC
AGENTS FOR THE TREATMENT OF
DIABETES**

)
) **Group Art Unit: 1617**
)
) **Examiner: Jiang, Shaojia A.**
)
) **Customer No.: 36183**
)
)
)
)
)
)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the Applicant's duty under 37 CFR § 1.56, the following information is brought to the attention of the Examiner.

CERTIFICATE OF MAILING
(37 CFR §1.8 a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

MARCH 2, 2005

Date of Delivery

Jocelyn B. Onzhangco

Name of Person Delivering Paper

Jocelyn B. Onzhangco

Signature of Person Delivering Paper



REFERENCES

- ☒ The references are listed on the attached Form PTO/SB/08a and copies are enclosed for the convenience of the Examiner.
- ☐ Copies of the references listed on the attached Form PTO/SB/08a have already been submitted in corresponding Patent Application No. _____ and therefore, copies of the same are not enclosed.
- ☐ Copies of U.S. Patent documents are not enclosed herewith.

The items identified in this Supplemental Information Disclosure Statement may or may not be “material” pursuant to 37 CFR § 1.56 and the submission thereof by Applicant shall not be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as “prior art” 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information, as defined in 37 CFR § 1.56, exists.



DISCLOSURE

☐ The attached Supplemental IDS is being filed in accordance with 37 CFR §§ 1.97 and 1.98. This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b)(3), that is before the mailing of a first Office Action on the merits. Thus, no petition or fee is required. However, if the undersigned representative of Applicant is in error in this regard, then the Examiner is requested to consider this IDS as filed under § 1.97(c)

☐ The attached Supplemental Information Disclosure Statement is being filed in accordance with 37 CFR §§ 1.97(c) and 1.98. This IDS is being filed after an action on the merits but before a Final Action under § 1.113 or a Notice of Allowance under § 1.311. In the event that this IDS is not received before a Final Action under § 1.113 or a Notice of Allowance under § 1.311, the Applicant respectfully requests the filing of these papers to be considered a petition requesting consideration of this IDS pursuant to 37 CFR § 1.97(d).

☒ The attached Supplemental Information Disclosure Statement is being filed in accordance with 37 CFR §§ 1.97(d) and 1.98. This IDS is being filed after receipt of a final action but before receipt of a Notice of Allowance Under § 1.311.



Statement Under 37 C.F.R. 1.97(e)(1) and 1.97(e)(2)

☐ I certify that pursuant to 37 CFR 1.97(e)(1), each item of information contained in this Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office (International Search Report) in a counterpart foreign application not more than three months prior to the filing of the Supplemental Information Disclosure Statement.

☐ I certify that pursuant to 37 CFR 1.97(e)(2), no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the best of my knowledge, no item of information contained in this Information Disclosure Statement was known to any individual more than three months prior to the filing of this Information Disclosure Statement.

PAYMENT METHOD

☐ Enclosed is a check to cover the fee pursuant to 37 CFR § 1.17(p).

☒ The Examiner is hereby authorized to charge any fee due with this filing to our Deposit Account No. **50-2613**.

☐ The Examiner is hereby authorized to charge any additional fee(s) required by this paper to our Deposit Account No. **50-2613**.



Respectfully submitted,

PAUL, HASTINGS, JANOFSKY & WALKER LLP

Dated: 3/1/05

By: Diana L. Bush

Diana L. Bush, Ph.D., Esq.
Reg. No. 51,109

P.O. Box 919092
San Diego, California 92191-9092
Telephone: (858) 720-2500
Facsimile: (858) 720-2555



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Copyright Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**SUPPLEMENTAL INFORMATION
DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	09/900,364
Filing Date	July 05, 2001
First Named Inventor	Erion et al.
Art Unit	1617
Examiner Name	Jiang, Shaojia A.
Attorney Docket Number	45198.00037.CIP

Sheet	1	of	1
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	ERION et al. Book of Abstracts, 219th ACS National Meeting, San Francisco, CA March 26-30 2000 (2000), COMP-029. American Chemical Society: Washington D.C.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2.0 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Patent
45198.00037.CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Erion et al.

Serial No.: 09/900,364

Filed: July 05, 2001

For: A COMBINATION OF FBPA
INHIBITORS AND ANTIDIABETIC
AGENTS FOR THE TREATMENT OF
DIABETES

)
) **Group Art Unit: 1617**
)
) **Examiner: Jiang, Shaojia A.**
)
) **Customer No.: 36183**
)
)
)
)
)
)

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed are the following documents:

- Supplemental Information Disclosure Statement;
- Form PTO/SB/08A;
- One (1) cited reference; and
- Return Postcard;

No fee is believed due with this submission; however, the Commissioner is authorized to charge any fee required to our Deposit Account No. 50-2613.

CERTIFICATE OF MAILING
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with anything referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

March 2, 2005

Date of Deposit
SAN/110017.1

Jocelyn B. Ongehango
Name of Person Mailing Paper
Jocelyn B. Ongehango
Signature of Person Mailing Paper

Respectfully submitted,

PAUL, HASTINGS, JANOFSKY & WALKER LLP

Dated: 3/1/05 By: Diana L. Bush
Diana L. Bush, Ph.D., Esq.
Reg. No. 51,109

PAUL, HASTINGS, JANOFSKY & WALKER LLP
P.O. Box 919092
San Diego, CA 92191-9092
Phone: (858) 720-2500
Fax: (858) 720-2555